Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Support par Telegram Messenger pour l'arrêt du tabac après un infarctus du myocarde (TELEGRAM-MI)

4 novembre 2026 mis à jour par: Mikhail Kuznetsov, ITMO University

Effet d'une intervention comportementale délivrée via Telegram Messenger sur l'arrêt du tabac chez les patients après un infarctus du myocarde : l'essai contrôlé randomisé TELEGRAM-MI

This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).

Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:

  • INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.
  • CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.

The primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.

This study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.

Aperçu de l'étude

Description détaillée

The TELEGRAM-MI trial is a multicenter, randomized, controlled, assessor-blinded superiority study testing a digital behavioral intervention for smoking cessation in post-myocardial infarction patients.

BACKGROUND: Smoking cessation is the most effective modifiable risk factor for reducing mortality after MI, yet long-term abstinence remains challenging due to limited sustained support. Digital interventions using popular messaging platforms offer a scalable solution to bridge the post-discharge support gap.

OBJECTIVES:

Primary: To determine if a 6-month Telegram chatbot intervention increases 30-day point prevalence abstinence rates at 6 months compared to standard care alone.

Secondary: To examine associations between baseline characteristics (nicotine dependence, motivation), engagement metrics, and cessation success; and to assess intervention acceptability.

METHODS: Approximately 142 participants will be recruited from inpatient cardiology departments. After providing informed consent, participants will be randomized 1:1 via the chatbot to either the intervention group (standard care plus 6-month behavioral support) or control group (standard care plus data collection only). The intervention incorporates evidence-based techniques including motivational messaging, cognitive-behavioral strategies, and relapse prevention protocols.

OUTCOMES: The primary outcome is biochemically unverified 30-day point prevalence abstinence at 6 months, assessed via blinded telephone interview with participant and relative verification. Secondary outcomes include various smoking behavior metrics collected through the chatbot platform.

ANALYSIS: Primary analysis will follow intention-to-treat principles, with missing data imputed as smoking. Statistical analyses will include chi-square tests for primary outcome and regression models for secondary outcomes.

POTENTIAL IMPACT: If effective, this intervention represents a readily implementable, low-cost strategy to enhance secondary prevention in cardiac patients.

Type d'étude

Interventionnel

Inscription (Estimé)

142

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Mikhail A. Kuznetsov, MD
  • Numéro de téléphone: +79170610352
  • E-mail: mihkuzn@gmail.com

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Ulyanovsk, Russie
        • Recrutement
        • Ulyanovsk Regional Clinical Hospital
        • Contact:
          • Administration of Clinical Hospital
          • Numéro de téléphone: +7 8422 32 32 71
          • E-mail: uokb@med.ulgov.ru
    • Ulyanovsk Oblast
      • Ulyanovsk, Ulyanovsk Oblast, Russie, 432000
        • Pas encore de recrutement
        • Ulyanovsk Regional Clinical Hospital
        • Contact:
          • Mikhail A. Kuznetsov, MD
          • Numéro de téléphone: +79170610352
          • E-mail: mihkuzn@gmail.com
        • Contact:
        • Chercheur principal:
          • Mikhail A. Kuznetsov, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Willing and able to provide written informed consent.
  • Age 18 years or older.
  • Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI), enrolment occurring either during index hospitalization or within 1 month post-MI at an outpatient visit
  • Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.
  • Regular user of the Telegram messenger application (app installed on a personal smartphone).
  • Possession of a smartphone with internet access and a valid phone number.
  • Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.

Exclusion Criteria:

  • Smoking cessation more than 1 month prior to the index MI hospitalization.
  • Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual/hearing impairment, inability to read or respond to messages).
  • Inability to read and understand the Russian language fluently.
  • Comorbid condition with a life expectancy of less than 1 year.
  • Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.
  • Unwillingness or inability to provide contact details for a close relative for outcome verification.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Telegram Bot Intervention Group

Participants receive standard care PLUS the 6-month behavioral intervention delivered via the Telegram chatbot.

A 6-month behavioral intervention delivered via a Telegram chatbot. The intervention includes personalized daily motivational messages, cognitive-behavioral techniques for craving management, access to an SOS/craving support button, weekly check-ins, and relapse prevention protocols. Content is tailored based on user responses to questionnaires (Fagerström Test, Importance/Confidence scales) and engagement metrics.

Autre: Standard Care Control Group

Participants receive standard care only. They are connected to the Telegram bot but only complete baseline and follow-up surveys without receiving any active smoking cessation content.

Routine physician advice to quit smoking provided upon hospital discharge. This represents the current standard of care in the participating clinical centers.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
30-day point prevalence abstinence (PPA)
Délai: 6 months

Proportion of participants who report abstinence from smoking for the past 30 days or more, verified by both participant self-report AND corroborating report from a close relative or cohabiting person during a telephone interview conducted by a blinded assessor. A positive outcome is recorded ONLY if both sources confirm abstinence. Participants with missing data (e.g., lost to follow-up) will be considered smokers in the primary analysis (intention-to-treat).

6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
7-day point prevalence abstinence (7-day PPA)
Délai: 1 month and 3 months

Proportion of participants who report abstinence from smoking for the past 7 days. Assessed via the Telegram bot.

1 month and 3 months
Change in cigarette consumption
Délai: Baseline, 1 month, 3 months, and 6 months

Change from baseline in the self-reported number of cigarettes smoked per day. Assessed via the Telegram bot.

Baseline, 1 month, 3 months, and 6 months
Score on the Fagerström Test for Nicotine Dependence (FTND)
Délai: Baseline and 6 months

Change in nicotine dependence measured by the FTND questionnaire (score range 0-10, higher scores indicate greater dependence). Assessed via the Telegram bot.

Baseline and 6 months
Motivation to quit (Importance and Confidence Scales)
Délai: Baseline and 6 months

Scores on self-rated scales (0-10) for the importance of quitting and confidence in the ability to quit. Assessed via the Telegram bot.

Baseline and 6 months
Participant engagement with the Telegram bot
Délai: 6 months

Composite measure of engagement (dose) including: proportion of completed weekly check-ins, proportion of opened messages, number of SOS/craving button uses, number of active weeks. Metrics are automatically logged by the bot.

6 months
Intervention acceptability and satisfaction
Délai: 6 months

Total score on a custom acceptability and satisfaction questionnaire (5-12 items) completed by participants in the intervention group via the Telegram bot. Higher scores indicate higher satisfaction.

6 months
Time to first relapse
Délai: 6 months

Number of days from randomization to the first self-reported relapse (lapse) event. Assessed via continuous monitoring through the bot's check-in system.

6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Mikhail Kuznetsov, MD, Ulyanovsk Regional Clinical Hospital
  • Directeur d'études: Dmitry Sergeev, PhD, ITMO University
  • Directeur d'études: Artemiy Okhotin, MPH, ITMO University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 juillet 2026

Achèvement primaire (Estimé)

27 avril 2027

Achèvement de l'étude (Estimé)

1 août 2027

Dates d'inscription aux études

Première soumission

13 novembre 2025

Première soumission répondant aux critères de contrôle qualité

14 novembre 2025

Première publication (Réel)

17 novembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All individual participant data collected during the trial, after de-identification, will be shared. This includes demographic data, smoking history, questionnaire responses (Fagerström Test, Importance/Confidence scales), intervention engagement metrics, and primary/secondary outcome data.

Délai de partage IPD

Beginning 12 months after main results publication and ending 5 years after publication. Data will be available for this period.

Critères d'accès au partage IPD

Data will be available to researchers who provide a methodologically sound research proposal approved by an independent review committee. Proposals should be directed to the corresponding author. Requestors will need to sign a data access agreement specifying the purpose of analysis, commitment to secure data handling, and agreement not to attempt re-identification of participants.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner